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ABSTRACT
Introduction: Risk scoring is an integral part of the
prevention of cardiovascular disease (CVD) and
should form the basis for the decision to offer
medication to reduce cholesterol (statins). However,
there is a suggestion in the literature that many
patients are still initiated on statins based on raised
cholesterol rather than a raised CVD risk. It is
important, therefore, to investigate the role that lipid
levels and CVD risks have in the decision to prescribe.
This research will establish how cholesterol levels and
CVD risk independently influence the prescribing of
statins for the primary prevention of CVD in
primary care.
Methods and analysis: The Health Improvement
Network (THIN) is a database of coded primary care
electronic patient records from over 500 UK general
practices. From this resource, a historical cohort will
be created of patients without a diagnosis of CVD, not
currently receiving a prescription for statins and who
had a lipid profile measured. A post hoc QRISK2 score
will be calculated for these patients and they will be
followed up for 60 days to establish whether they were
subsequently prescribed a statin. Primary analysis will
consist of predictive modelling using multivariate
logistic regression with potential predictors including
cholesterol level, calculated QRISK2 score,
sociodemographic characteristic and comorbidities.
Descriptive statistics will be used to identify trends in
prescribing and further secondary analysis will
explore what other factors may have influenced the
prescribing of statins and the degree of interprescriber
variability.
Ethics and dissemination: The THIN Data Collection
Scheme was approved by the South-East Multicentre
Research Ethics Committee in 2003. Individual studies
using THIN require Scientific Review Committee
approval. The original protocol for this study and a
subsequent amendment have been approved
(16THIN009A1). The results will be published in a
peer review journal and presented at national and
international conferences.
INTRODUCTION
Predicted risk of cardiovascular disease
(CVD) is determined from a combination of
age, sex and cardiovascular risk factors.1 2
Risk of CVD is the best predictor of the bene-
ﬁts of statins because statins have the same
proportional effect on people at low and
high risk.3 Because of this, assessment of pre-
dicted risk of CVD has been a fundamental
part of national clinical guidance on CVD
prevention in primary care since 1998.4 In
the UK, an absolute risk of CVD greater than
a threshold was, and remains, a criterion for
offering statin treatment and, in combination
with raised blood pressure, a criterion for
antihypertensive treatment.5–7 Risk assess-
ment is also embedded in clinical guidelines
around the world including New Zealand,
Europe and America.8–10 A variety of differ-
ent risk calculators are available and while
QRISK211 is the calculator of choice in
England and Wales, elsewhere, others such
as Framingham,1 Score,12 ASSIGN13 or
Procam14 are recommended.
Strengths and limitations of this study
▪ The use of a large, validated and generalisable
set of general practices gives an unparalleled
insight into current real-life medical practice.
▪ The use of a large cohort will allow the impact of
lipid profiles and cardiovascular disease risk esti-
mation to be modelled in an insightful and novel
way.
▪ Insight into the decision to prescribe statins is
limited to information that is coded in the elec-
tronic patient record and therefore much of the
decision-making process will remain unknown.
▪ Recording of data may be incomplete and there-
fore some approximations will have to be made.
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Statins are the only class of lipid-lowering medications
recommended for use in UK primary care5 and are the
most widely prescribed medication in England.15 A small
proportion of patients in England have to pay a prescrip-
tion charge for their medications but the majority
receive their medication free.16 Statins are used to lower
lipids as part of a CVD primary prevention strategy. As
estimated CVD risk is the best predictor of likely beneﬁts
of treatment this information is necessary for effective
shared decision-making when considering the use of
statins.17 Evidence suggests that usage of risk scoring
improves accuracy of perceived CVD risk and medical
prescribing without causing harms.18–20
In the context of primary prevention, there is evi-
dence both of undertreatment of high-risk patients
(above the treatment threshold) and inappropriate treat-
ment of low-risk patients (below the treatment thresh-
old).21–24 Moreover, patients with the highest absolute
CVD risk are at greatest risk of being undertreated.25
One reason for this is that risk scores may not be consist-
ently used by clinicians to guide decision-making.26
Reasons for not using risk score calculators include a
belief that risk scoring oversimpliﬁes the decision and
may lead to overprescribing27 and confusion over how
best to use risk score calculators.28
Additionally, one fundamental barrier to using risk
scores is a focus on individual risk factors over absolute
risk score.22 29 It may appear logical that decisions about
initiating cholesterol-lowering medication should be
based on the patient’s cholesterol level, and indeed this
was the preferred approach in the pre-CVD risk era.30 31
However, this approach would not necessarily result in
the greatest beneﬁts and is not justiﬁable based on the
available evidence. Despite this, there is evidence that
this approach prevails in some areas. After adjusting for
other CVD risk factors, lipid proﬁle has been found to
predict statin initiation in a US study32 and a rando-
mised theoretical experiment in Australia highlighted
clinicians’ preferences for managing individual risk
factors over absolute risk.33 To further compound the
problem, patients ﬁnd it difﬁcult to make decisions
based on future risks and tend to preferentially focus on
cholesterol levels when considering taking statins.34 35
In 2014, guidelines for England and Wales on lipid
modiﬁcation reduced the predicted risk threshold at
which patients should be offered statins from a 20%
10-year risk to 10%.5 7 This recommendation was met
with considerable concern from the medical community
that it would lead to widespread overprescribing of
statins with little clinical beneﬁt but considerable poten-
tial for harm.36 37 This widely publicised criticism may
have increased concerns that risk scoring leads to over-
simpliﬁcation of clinical decisions and overprescribing
and may have, perversely, decreased the use of risk
scoring and reinforced the use of lipid levels to guide
decision-making. There is some evidence to suggest
there was a decrease in statin initiations around this time
due to the negative media attention.38
This research will investigate the relationship between
lipid proﬁle, QRISK2 score and subsequent initiation of
statins by primary care clinicians. This will give an indi-
cation of the patient factors that are inﬂuencing the
decisions clinicians make in routine practice when con-
sidering the use of statins and how this has changed in
response to external factors.
The consistent use of risk scoring can result in more
targeted prescribing and fewer patients being prescribed
medication overall39 which maximises the efﬁciency and
cost-effectiveness of treatment at a population level.
AIMS AND OBJECTIVES
Aim: To establish whether UK primary care patients are
initiated on statins based more on their lipid levels or on
their predicted CVD risk and if this has changed over
time.
Objectives:
For primary prevention of CVD
1. To evaluate how lipid levels and CVD risk independ-
ently predict subsequent prescribing of statins.
2. To determine if the relationship between lipid levels,
QRISK2 score and statin prescribing has changed fol-
lowing recent guideline changes.
3. To investigate the contribution that calculating a
QRISK2 score has on the probability of initiating
statin therapy.
4. To investigate interprescriber variation when initiat-
ing statins.
METHODS AND ANALYSIS
Study design
A historical open cohort study of patients who were
eligible for statin therapy for the primary prevention
of CVD.
Data source
Data will be extracted from anonymised primary care
records from practices in England and Wales who con-
tribute to The Health Improvement Network (THIN)
database. The THIN database contains routine patient
data from over 500 UK general practices which are gen-
eralisable to the UK population.40 THIN has been used
in previous studies to validate QRISK2 and it was shown
that the discrimination statistics in THIN are as good as
those for the original QRISK2 cohort.41 42 Practices that
contribute to THIN use the Vision (In Practice Systems)
electronic patient records system. Clinical data are
coded using Read code clinical classiﬁcation V.243 and
drug codes are used which correspond to the British
National Formulary (BNF).44 The clinical codes used
are available in online supplementary appendix I and
the drug codes are available in online supplementary
appendix II.
All data are anonymised and will be stored on secure
severs at the University of Birmingham and accessed
only through password-protected systems.
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Population
Patients will be eligible for inclusion if they are aged
between 40 and 84 years inclusive (the age range recom-
mended by the National Institute for Health and Care
Excellence (NICE) for risk assessment5) with no previ-
ous diagnosis of CVD and at least one lipid result coded
in the study period. The date of the ﬁrst coded lipid
result in the study period will be considered the index
date. Patients must not have been prescribed a statin
prior to the index date.
In order to maintain a stable cohort of practices, only
THIN practices in which there are data available for the
whole study period will be included. The study period
will run from the beginning of 2012 to the end of 2016.
Patients will be eligible for inclusion from the earliest of
the following dates: study start date, acceptable mortality
reporting date (which ensures that patient deaths and
deregistrations are being recorded consistently45), Vision
date plus 1 year, registration date plus 1 year (to ensure
time for baseline data to be recorded), and age 40; until
the earliest of the following dates: age 85, study end
date, CVD diagnosis, other excluding diagnosis (as
below), statin initiation or recording of a contraindica-
tion for the prescribing of statins. Patients will also be
excluded if they left the database within 60 days of the
index date.
Patients will be excluded if they had pre-existing CVD,
were pregnant, had a contraindication to statin therapy
(including allergies and drug interactions), were already
being prescribed a statin (or other lipid-lowering
therapy) or had ever been prescribed a statin in the
past. Patients will be considered to have pre-existing
CVD if they had a diagnosis of myocardial infarction,
angina, peripheral vascular disease or stroke/transient
ischaemic attack. Patients with type 1 diabetes mellitus, a
diagnosis of chronic kidney disease stages 3–5 and
patients diagnosed with or who were at risk of familial
hypercholesterolaemia will also be excluded as statin use
in these patients should not be based on CVD risk
assessment. Patients at risk of familial hypercholestero-
laemia will be deﬁned as those with a total cholesterol of
≥9.0 mmol/L as this is the threshold for seeking specia-
list assessment deﬁned in the NICE guidance.5
STUDY VARIABLES
Exposure variables
The exposure of interest is the undertaking of lipid
testing. Once a patient has their lipids recorded, this
signiﬁes that a clinician has made a decision about the
signiﬁcance of the lipid levels and will act on this.
Individual patients may have multiple lipid results
recorded over the study period. Assuming the exclusion
criteria are not met, each lipid result will be considered
as a new exposure so long as it is not within 60 days of
the last recorded lipid level. The number of previous
lipid results will be included in predictive modelling.
Outcome variables
The outcome will be the prescription of a statin within
60 days of a set of lipid results.
Predictor variables
Sociodemographic details will be obtained for each
patient: age, sex, ethnicity, Townsend quintile and rura-
lity indicator (see online supplementary appendix III).
General practice and clinician ID will also be recorded.
Patient variables will include the cardiovascular risk
factors required to calculate QRISK2; age, sex, ethnicity,
postcode, smoking status, diabetes status, family history
of CVD, CKD (stage 4 or 5), atrial ﬁbrillation, hyperten-
sion treatment, rheumatoid arthritis, lipids, blood pres-
sure and body mass index (BMI). Other clinical data
that may affect the decision to prescribe statins will also
be collected comprising of; liver transaminase levels, sys-
temic inﬂammatory conditions, severe mental health
conditions and HIV.
Data on medication prescriptions will be extracted.
Patients who received a prescription for antihypertensive
medication up to 180 days prior to the index date will be
considered to have been on treatment for hypertension.
Prescriptions of antipsychotics, corticosteroids and
immunosuppressant medication will be recorded as
these may change the threshold for prescribing
lipid-lowering medication.
All included patients will have a QRISK2 score calcu-
lated post hoc from the available data. In addition, any
coded QRISK2 score prior to and including the
follow-up period will be extracted.
The date when predictor variable data are collected
will vary depending on whether or not the patient has a
QRISK2 score coded during the follow-up period. For
patients with a coded QRISK2 score on the index date
or in the follow-up period, the date of QRISK2 record-
ing will be used as the date for collecting data on pre-
dictor variables and the most recent data (including the
date of QRISK2 coding) will be recorded. If more than
one QRISK2 score is coded in the follow-up period, the
latest date will be used for data collection to account for
any variables that were updated during the follow-up
period. For patients who do not have a coded QRISK2
score, the included data will be the most recent
recorded before and including the end of the 60-day
follow-up period.
Missing data and extreme values
Missing data are anticipated in some variables; notably
BMI, blood pressure and smoking status. If comorbidi-
ties are missing they will be assumed to be absent.
Missing values arise twice: ﬁrst when calculating the
QRISK2 score post hoc, and second when constructing
the multivariable model. These citations will be
accounted for differently.
Where data are missing from variables used in
QRISK2 calculations, the imputed values used by the
QRISK2 calculator will be used.46 In the multivariable
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model, all variables will be categorical and a ‘missing’
category will be used to account for the possibility that
missing data are associated with the initiation of statins.
Biologically implausible values for blood pressure, lipids,
liver transaminases, height and weight will be identiﬁed
and excluded.
ANALYSIS
Continuous variables will be categorised. Calculated and
coded QRISK2 scores will be categorised according to
risk bands (<10%, 10–14.9%, 15–19.9% and ≥20%). Age
will be categorised into four groups (40–49, 50–59, 60–
69 and ≥70). Total cholesterol (TC) will be categorised
into three bands (<5.0, 5.0–6.9 and ≥7.0 mmol/L), and
high-density lipoprotein (HDL) cholesterol into four
bands (≤1.2, 1.3–1.4, 1.5–1.7 and ≥1.8 mmol/L) as these
cut-offs have been used previously in the literature.22
Systolic blood pressure will be split into three groups cor-
responding to normotensive, stage 1 hypertension and
stage 2 hypertension (<140, 140–159 and ≥160 mmHg).6
The cohort will be described and prescribing rates
and QRISK2 score trends will be established.
The primary analysis will consist of predictive modelling
using multivariate logistic regression (variables sum-
marised in table 1). Clustering of responses within individ-
ual general practitioner (GP) practices will be included in
the model. Variation throughout the year due to the sea-
sonality imposed by the Quality and Outcomes Framework
(QOF) targets will be accounted for by adding the year
quarter as a variable in the model. Assuming a minimum
sample size for analysis of 10 per degree of freedom,47
and 57 degrees of freedom in the variables, a minimum
sample of 570 patients with a lipid proﬁle and subsequent
statin initiation should easily be obtained.
The potential cohort size can be estimated from the
literature. Feasibility data from the THIN database iden-
tiﬁed over 360 000 patients over 2 years who were eli-
gible for statin treatment for the primary prevention of
CVD and had a lipid result and blood pressure coded
on their medical record.22 Over a 5-year period we
should expect to identify over double this number.
Another cohort identiﬁed just over two million patients
in the THIN database in the age range where NHS
health checks are offered.48 Given that every patient
who attends an NHS health check should have a lipid
test undertaken and 20% of 40–75 years old are invited
to have a health check each year, with ∼50% taking up
this offer.49 This would generate around 200 000 coded
lipid results in the target population annually.
The accuracy of the post hoc QRISK2 calculations will
be tested through comparisons with corresponding
coded QRISK2 scores in patients where these are
available.
Additional modelling will also be undertaken to con-
sider whether having a QRISK2 score coded on the
medical record affects the probability of having a statin
prescribed after adjustment for the level of CVD risk.
Secondary analysis will also establish whether the thresh-
old for initiating statins has changed over the course of
the study period. The mean lipid levels and QRISK2
scores (both coded and calculated post hoc) of those
initiated on statins and those not initiated on statins will
be calculated each year to reveal any trends in the
thresholds for initiation.
Finally, prescriber-level data will be analysed to estab-
lish whether individuals tend to be inﬂuenced more by
lipid levels or risk score when initiating stains and
whether this behaviour is consistent over time. A score
that illustrates the propensity to prescribe based on lipid
levels will be calculated for individual clinicians. This
will be generated by comparing the number of statin
Table 1 Variables used in predictive modelling
Variable Categories
Total cholesterol <5.0, 5.0–6.9, ≥7.0
TC/HDL ratio ≤1.2, 1.3–1.4, 1.5–1.7, ≥1.8
Prior cholesterol
measurements
0, 1–2, 3–4, ≥5
Calculated QRISK2 <10%, 10–14.9%, 15–19.9%,
≥20%
Coded QRISK2 <10%, 10–14.9%, 15–19.9%,
≥20%, missing
Systolic BP <140, 140–159, ≥160,
missing
Age 40–49, 50–59, 60–69, ≥70
Sex Male, female
Ethnicity White, Asian, black, other,
missing
Townsend deprivation
quintile
1st, 2nd, 3rd, 4th, 5th, missing
Urban/rural score Urban, rural, missing
BMI <20, 20–24.9, 25–29.9,
30–34.9, 35+, missing
Smoking status Current smoker, ex-smoker,
non-smoker, missing
Liver transaminases Normal, abnormal, missing
Diabetes mellitus Yes, no
Family history of CVD Yes, no
Atrial fibrillation Yes, no
Rheumatoid arthritis Yes, no
Hypertension Yes, no
Chronic kidney disease Yes, no
HIV Yes, no
Severe enduring mental
illness*
Yes, no
Inflammatory conditions† Yes, no
Antipsychotic medication Yes, no
Long-term corticosteroids Yes, no
Immunosuppressant
medication
Yes, no
Year quartile 1st, 2nd, 3rd, 4th
*Schizophrenia, bipolar affective disorder, mania or psychosis
(unspecified), psychotic depression.
†Systemic lupus erythematosus, scleroderma, Bechet’s syndrome,
other inflammatory arthritis.
BMI, body mass index; BP, blood pressure; CVD, cardiovascular
disease; HDL, high-density lipoprotein.
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initiations to patients with a total cholesterol of
≥6.5 mmol/L with the number of statin initiations to
patients with a total cholesterol of <6.5 mmol/L. Only
clinicians who initiated 10 or more statin prescriptions
over the study period will be analysed as scores for clini-
cians with fewer initiations may not be representative of
their behaviour. The distribution of these scores will be
described. For clinicians who initiated statins in every
year of the study, their score will be calculated for the
2-year periods 2012–2013 and 2015–2016. The scores for
each period will be split into quintiles. The tendency for
clinicians to stay in the same quintile, or move quintile,
will then be described.
POTENTIAL LIMITATIONS
The use of electronic patient records, while excellent for
allowing access to large quantities of real-life data, does
not allow complete understanding of the decision-
making process. We will not be able to explore why a
patient with a particular lipid proﬁle does or does not
receive a prescription for a statin. We cannot gain insight
into what discussion took place as to the risk and beneﬁts
of treatment or even whether the clinician discussed the
lipid result and CVD risk with the patient. It is also difﬁ-
cult to know to what extent clinicians are using QRISK2
scores in their decision-making process because, as only
coded data are available, QRISK2 score may be calculated
but not recorded in GP records. The Vision patient
record system automatically displays a CVD risk score for
patients who may beneﬁt from CVD risk reduction46 and
the clinician could act on this information without it
being coded. This would result in patients being pre-
scribed a statin based on their CVD risk without this
being apparent through the coded information.
It is also possible that some patients will have their
lipid levels checked outside of the primary care system
(either in secondary care or the private sector) and may
be started on statins by their GP without the lipid levels
being recorded in primary care. These patients would
not be included in this cohort. However, it is unlikely
that this will represent a signiﬁcant proportion of
patients initiated on statins. Similarly, a small proportion
of patients may be initiated on statins by secondary care
or private clinicians and the prescription continued by
their GP. In this scenario, the GP may not be involved in
the decision-making process but this would not be iden-
tiﬁed from the data. Again, this is likely to be a very
small proportion of the total statin initiations in the UK
and is not of central interest as the decision to prescribe
was made outside the primary care setting and is, there-
fore, unlikely to affect the validity of our conclusions.
In conclusion, while the methodology will not facili-
tate complete understanding of the individual decision-
making consultations, it will provide new and valuable
insight into the way that lipid levels and cardiovascular
risk are currently being used in primary care to inform
the decision to prescribe or offer statins. We will be able
to establish whether the use of risk scoring is resulting
in more evidence-based prescribing and improve under-
standing of some of the factors affecting decision-
making which may inform future policy and clinical
guidance.
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